作者
Davide Campana, Gabriele Capurso, Stefano Partelli, Francesca Nori, Francesco Panzuto, Domenico Tamburrino, Giulia Cacciari, Gianfranco Delle Fave, Massimo Falconi, Paola Tomassetti
发表日期
2013/8
期刊
European journal of nuclear medicine and molecular imaging
卷号
40
页码范围
1197-1205
出版商
Springer Berlin Heidelberg
简介
Purpose
Peptide receptor radionuclide therapy (PRRT) is a relatively new treatment modality for patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs). The aim of this study was to determine the time to progression of patients treated with PRRT and to identify the prognostic factors related to treatment response.
Methods
Patients with sporadic GEP NETs prospectively treated with PRRT were retrospectively analysed. The primary end point was progression-free survival (PFS).
Results
A total of 69 patients (37 men and 32 women; 45 with pancreatic and 24 with gastrointestinal lesion; 22 NET G1 and 41 NET G2) were treated with 90Y or 177Lu. The objective response rate was 27.5 % (partial response, PR), while 50.7 % had stable disease and 23.2 % had progressive …
学术搜索中的文章
D Campana, G Capurso, S Partelli, F Nori, F Panzuto… - European journal of nuclear medicine and molecular …, 2013